Curetis AG, a Holzgerlingen near Stuttgart, Germany-based molecular diagnostics company which focuses on the development and commercialization of products for diagnosing severe infectious diseases, has raised €9.6m in Series A expansion financing.
The round was led by Forbion Capital Partners, with participation from Roche Venture Fund, CD-Venture and management.
This brings the amount raised by the company in Series A round to €34.1m.
Founded in 2007 and led by CEO Oliver Schacht, PhD, and CTO Andreas Boos, and COO Johannes Bacher, Curetis is developing diagnostic solutions (The Unyvero™ System) designed to enable rapid multiparameter pathogen and antibiotic resistance detection in a few hours. It will allow physicians to diagnose the cause of the infection faster and commence the appropriate targeted antibiotic regimen immediately in critically ill patients.
In conjunction with the funding, Holger Reithinger, Partner at Forbion CapitalPartners, has joined Curetis’ Board of Directors. Roche will get an observer seat on the Board.